|Hospital:||Erasmus Medical Center|
|Patients: This Phase II study involved 27 patients with malignant pleural mesothelioma. None of these patients had been administered prior chemotherapy.|
Treatment: The treatment consisted of the chemotherapy drug, temozolomide (temodar).
Toxicity: Grade 3-4 toxicities included hematologic, infection, nausea, vomiting, and arthralgia.
Results: The median overall survival from the time the patient registered in the study was 8.2 months.
Support: Schering-Plough International supported this study. Schering-Plough markets temodar.
Correspondence: J.P. van Meerbeeck